Monthly Archives: September 2017

Venturing Boldly Into Neuroscience
September 21, 2017

Neuroscience has quietly become a hot space for startups. Across a range of neurologic conditions, contrarian investors have been fueling entrepreneurs to discover and develop novel therapeutic strategies. Earlier this week, two Atlas-founded companies, Rodin Therapeutics and Disarm Therapeutics, both announced

Leave a comment

Alternative Perspectives On The Biotech M&A Environment
September 7, 2017

Last month, Bloomberg bemoaned the dearth of biotech M&A, and pundits echoed the sentiment (here, here), citing concerns about tax rates and drug pricing. The top line numbers in Bloomberg’s graph certainly paint a dim view of 2017’s global biotech

1 Comment

New Blood Needed: Pharma R&D Leadership Tenure
September 5, 2017

It’s all about people, it always is. Human capital is a company’s most important asset. Successful companies have human capital management strategies that excel at talent recruitment, and prioritize career development and retention. But human capital is never static, and

Leave a comment